Other Latest News

• Europe: Shares stumble on Trump’s new tariff threat The Business Times Singapore EUROPEAN shares began June on a dour note as markets grappled with US President Donald Trump’s new tariff plans that threatened to reignite a fresh wave of global trade tensions. The continent-wide Stoxx 600 slipped 0.14 per cent to 547.92 on Monday, after …
• Theravance Biopharma To Sell Remaining Interest In Trelegy Ellipta To GSK For $225 Mln, Stock Up RTTNews Theravance Biopharma, Inc. (TBPH), Monday announced an agreement to sell remaining interest in net sales of Trelegy Ellipta, a chronic obstructive pulmonary disease or asthma treatment, to GSK (GSK) for $225 million in cash. This move comes as a result of …
• The UK’s last shot at AI relevance Unherd Britain deceives itself. We deceive ourselves about our history, and we deceive ourselves about the lessons of that history. Orwell compared Forties England to a Victorian family, its cupboards bursting with skeletons, its members exhibiting “a deep …
• Adding lutetium (177Lu) vipivotide tetraxetan to SOC improves rPFS in mHSPC Urology Times The phase 3 PSMAddition trial (NCT04720157) has met its primary end point, demonstrating that the addition of lutetium (177Lu) vipivotide tetraxetan (177Lu-PSMA-617; Pluvicto) to standard of care (SOC) hormone therapy significantly improved radiographic …
• UROGEN ALERT: Bragar Eagel & Squire, P.C. Announces that a Class Action Lawsuit Has Been Filed Against UroGen Pharma Ltd. and Encourages Investors to Contact the Firm EIN Presswire NEW YORK, June 02, 2025 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, announces that a class action lawsuit has been filed against UroGen Pharma Ltd. (“UroGen” or the “Company”) (NASDAQ:URGN) in …
• World News | Jaishankar, Paraguay Foreign Minister Sign MoU to Establish Joint Commission Mechanism Latestly New Delhi [India], June 3 (ANI): India and Paraguay on Monday signed a Memorandum of Understanding (MoU) to establish a Joint Commission Mechanism (JCM). The agreement was signed by External Affairs Minister, S Jaishankar, and Paraguay Foreign Minister …
• Angelman Syndrome Market to Witness Significant Growth Through 2034, Driven by Novel Therapeutic Advancements | DelveInsight WFMZ - Pennsylvania According to DelveInsight's estimates, the Angelman syndrome market size in the 7MM is expected to show positive growth during the forecast period (2025–2034), primarily driven by the increasing prevalence of Angelman syndrome, growing awareness and …
• Jazz Pharmaceuticals Announces Zepzelca® (Lurbinectedin) And Atezolizumab (Tecentriq®) Combination Significantly Improves Survival As First-Line Maintenance Therapy For Extensive-Stage Small Cell Lung Cancer MENAFN (MENAFN- PR Newswire) First-line maintenance combination therapy reduced the risk of disease progression or death by 46%, with a median overall survival of 13.2 months vs 10.6 months for atezolizumab alone from the point of randomization First Phase 3 …
• How Top Life-Science Regions Position Themselves To Generate Value and a Biomanufacturing Leverage Point: A New Tool To Facilitate Comparative Analysis BioProcess International HTTPS://STOCK.ADOBE.COM The COVID-19 pandemic placed deep public scrutiny on the global biologic landscape. Concerns arose from the inability to procure nationally developed or manufactured vaccines, a lack of suitable and readily available …
• After 4 Months, Elon Musk Learned What Every American Already Knows, Says Ross Gerber: 'No One In Government Wants To Cut Any Budget' Benzinga Tesla TSLA CEO and former Trump administration adviser Elon Musk is learning a hard truth about Washington, according to investor Ross Gerber. “After 4 months Elon learned what every natural born American already knows. No one in the government wants to ‘ …
• UroGen Pharma Ltd. (URGN) Faces Securities Class Action Amid FDA’s Briefing Document and Subsequent ODAC Vote Against UGN-102 – Hagens Berman EIN Presswire SAN FRANCISCO, June 02, 2025 (GLOBE NEWSWIRE) -- A securities class action lawsuit styled Cockrell v. UroGen Pharma Ltd. et al., No. 3:25-cv-06088 (D. N.J.) has been filed and seeks to represent investors who purchased or otherwise acquired UroGen …
• Biomednewsbreaks Nutriband Inc. (NASDAQ: NTRB) Posts Record Q1 Revenue, Advances AVERSA Fentanyl Development MENAFN (MENAFN- Investor Brand Network) Nutriband (NASDAQ: NTRB) reported first-quarter revenue of $667,000, a 63% year-over-year increase driven by expanded kinesiology tape production through its Pocono Pharma subsidiary and growing retail presence at Target, …
• FDA accepts navepegritide application to treat children with achondroplasia Contemporary Pediatrics On June 2, 2025, the FDA accepted a new drug application for navepegritide (TransCon CNP; Ascendis Pharma A/S) to treat children with achondroplasia and has assigned a Prescription Drug User Fee Act date of November 30, 2025, for potential approval. …
• Sanofi picks up Blueprint in deal worth up to $9.5 billion, in rare immunological disease expansion Medical Marketing and Media Sanofi is expanding its presence in the rare immunological disease space with the acquisition of Blueprint Medicines Corporation. The pharma giant announced Monday that it would be buying the biopharma company to bolster its rare immunology pipeline in a …
• Immunic To Participate In Investor, Scientific And Industry Conferences In June MENAFN Issuer: Immunic AG / Key word(s): Conference 02.06.2025 / 12:30 CET/CEST The issuer is solely responsible for the content of this announcement. Immunic to Participate in Investor, Scientific and Industry Conferences in June NEW YORK, June 2, …
• Dermatology Month in Review: May 2025 HCPLive Every month, the HCPLive editorial team publishes a new iteration of our Month in Review series, during which a summary provides several highlights of the most notable news coverage from the month in each medical subfield. Here, the team spotlights some of …
• Ascendis Pharma: FDA Grants Priority Review For NDA For TransCon CNP RTTNews Ascendis Pharma (ASND) announced the FDA has accepted for priority review its New Drug Application for TransCon CNP for the treatment of children with achondroplasia and has set a PDUFA goal date of November 30, 2025 to complete its review. The FDA also …
• SCIEX unveils ZenoTOF 8600 system, AI‑powered software and Evosep partnership Research & Development World At ASMS 2025, SCIEX staked a claim on end‑to‑end, high‑throughput proteomics with three related announcements. First up was the launch of the ZenoTOF 8600 mass spectrometer with a 10‑fold sensitivity gain over its predecessor. Then there was a Windows‑11‑ …
• Mocktails, Steak Houses, and Barmaid Corsets: How MAGA’s Young Influencers Will Spend Their Summers Vanity Fair For the burgeoning scene of young conservative influencers, the going has never been better. A renewed coalition of women creating both lifestyle and political content has been brewing for years, with the support of right-leaning media properties like The …
• Oxipital AI and Schmalz Extend Partnership to Deliver Advanced Automated Solutions WFMZ - Pennsylvania BEDFORD, Mass., June 2, 2025 /PRNewswire/ -- Oxipital AI, a leading provider of AI-powered machine vision systems, is proud to welcome Schmalz into its Preferred Partner Program and to continue its long-standing collaboration with the company. …
• Rising Trade Tensions May Weigh On Wall Street RTTNews The major U.S. index futures are currently pointing to a lower open on Monday, with stocks likely to move to the downside after ending last Friday's volatile session little changed. Renewed trade concerns are likely to weigh on the markets amid further …
• INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of UroGen Pharma Ltd.  - URGN EIN Presswire NEW YORK, June 02, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of  UroGen Pharma Ltd. (“UroGen” or the “Company”) (NASDAQ: URGN).  Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or …
• This autoimmune disease has ravaged women for centuries. New treatments could finally change that AOL New Treatments Could Finally Treat Alopecia getty images getty imagesSince she was a child, Brandi Jones struggled with hair loss—not minor shedding or overall thinning, but large bald spots that made her feel like her head looked “like a leopard or …
• BMS outlays $11bn to join BioNTech’s development of bispecific cancer drug Pharmaceutical Technology Bristol Myers Squibb (BMS) is joining forces with BioNTech in a deal that could surpass $11bn as the two drugmakers look to take on the dominance of MSD’s Keytruda (pembrolizumab) in solid tumour treatment. The deal will see BMS partner with BioNTech on a …
• Pharmacy giants CVS, Walgreens and Rite Aid are closing hundreds of stores across Pennsylvania. Here's where. PhillyBurbs - Pennsylvania Pharmaceutical giant Rite Aid announced it was closing 316 stores as it filed for its second bankruptcy in May, and Pennsylvania will feel the strongest hit as 172 of the state's Rite Aid stores shutter. The news is the latest in a slew of big pharma …
• Second annual MIMS Pharma report provides new market insights MIMS The MIMS Pharma Market Insight Report 2025 brings together exclusive clinical insight and audience intelligence to provide pharmaceutical teams with an update on the state of play for primary care prescribing in five key therapeutic areas: cardiology, …
• Another major grocery chain to scoop up 78 Rite Aid stores and prescriptions are already getting transferred The U.S. Sun A POPULAR grocery chain has set its sights on saving a number of Rite Aid locations from permanent closure, and shoppers will see their prescriptions transferred automatically. As Giant Eagle swoops in to rescue the 78 Rite Aid stores, customers will …
• Ground Rent: FCTA threatens to revoke properties belonging to ex-FCT minister, 3, 382 other allotees [FULL LIST] Premium Times The Federal Capital Territory Administration (FCTA) has issued a 14-day ultimatum to the military, foreign embassies, religious groups, government agencies, and private property owners in Abuja to settle outstanding ground rent arrears or face revocation …
• Recludix Pharma Advances First-in-Class Oral STAT6 Inhibitor REX-8756 for Inflammatory Diseases, Including Atopic Dermatitis Dermatology Times Recludix Pharma announced today the nomination of its lead development candidate, REX-8756, an oral, reversible, and highly selective STAT6 inhibitor designed to address a wide range of type 2 inflammatory diseases, including atopic dermatitis.1 The …
• French pharma giant Sanofi to buy Biotech Blueprint for $9.1 bn Mint French pharmaceuticals giant Sanofi has agreed to buy Blueprint Medicines Corp. for at least $9.1 billion as the company aims to expand the company's reach in rare immunological diseases, reported the news agency Bloomberg on Monday, 2 June 2025. …
• The MAHA agenda won’t include expanding GLP-1 coverage — for now PharmaVoice The GLP-1 boom isn’t slowing down anytime soon. Prescriptions for overweight or obese adults jumped almost 587% from 2019 to 2024, Healthcare Dive reported, and there’s still a huge untapped patient population representing more market upside. As pharma’s …
• Hyperscale Data Fuels AI Ambitions With $4.65 Million Pharma Divestment Benzinga Hyperscale Data, Inc. GPUS on Monday disclosed that it has sold its minority equity stake in a private pharmaceutical firm for gross cash proceeds of $4.65 million. Hyperscale Data originally acquired this position for $1.5 million through multiple …
• Drugmaker Indivior to abandon London listing amid exodus of companies The Guardian The drugmaker Indivior has become the latest company to abandon its listing in London, heaping further pressure on the London Stock Exchange (LSE) to reinvigorate itself. The Virginia-based company, which makes the opioid addiction treatments Sublocade and …
• SMALL CAP IDEA: Poolbeg Pharma raises £4.1m finance development of its cancer treatments This Is Money Raising fresh capital is a familiar rhythm for early-stage biotech companies.  For Poolbeg Pharma, the question is not simply whether it can fund its ambitions, but whether its pipeline can justify them.  Expert opinion is broadly optimistic on this point …
• URGN STOCK: Suffer Losses on UroGen Pharma Ltd.? BFA Law Notifies Investors of Imminent July 28 Securities Class Action Deadline (NASDAQ:URGN) EIN Presswire NEW YORK, June 02, 2025 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against UroGen Pharma Ltd. (NASDAQ: URGN) and certain of the Company’s senior executives for potential violations …
• PEG-40 Hydrogenated Castor Oil Market to Reach $112.9M by 2031, Driven by Cosmetics Demand | DataM Intelligence EIN Presswire Explore how PEG-40 Hydrogenated Castor Oil is transforming cosmetics and pharma with strong growth projected through 2031. AUSTIN, TX, UNITED STATES, June 2, 2025 /⁨EINPresswire.com⁩/ -- PEG-40 Hydrogenated Castor Oil market reached US$ 60.1 …
• World News | PM Modi, Paraguayan Prez Pena Hold Talks on Agriculture, Pharma, Technology Latestly New Delhi [India], June 2 (ANI): Prime Minister Narendra Modi on Monday held talks with Paraguayan President Santiago Pena at Hyderabad House. The two leaders discussed enhancing cooperation in the fields on agriculture, Pharma, technology, renewable …
• Elizabeth Warren Agrees With Trump On Scrapping Debt Limit—But Blasts $4 Trillion Hike For Billionaire Tax Breaks Benzinga Sen. Elizabeth Warren (D-Mass.) expressed agreement with President Donald Trump on eliminating the federal debt ceiling while sharply criticizing proposed tax breaks for wealthy Americans amid escalating fiscal concerns. What Happened: Warren shared a …
• ASCO25: Regeneron unpacks positive Libtayo data in adjuvant CSCC as Keytruda stumbles Pharmaceutical Technology Regeneron has fleshed out additional positive data for blockbuster immunotherapy Libtayo (cemiplimab) as an adjuvant therapy in high-risk cutaneous squamous cell carcinoma (CSCC), as rival PD-1 inhibitor Keytruda falters in the same indication. Regeneron …
• NervGen Pharma Reports Positive Topline Data from the Chronic Cohort of its Phase 1b/2a Clinical Trial Evaluating NVG-291 in Spinal Cord Injury EIN Presswire Study met its primary endpoint by achieving statistical significance on one of its two pre-specified co-primary endpoints, demonstrating increased electrical connectivity between the brain and hand muscle in individuals with a cervical level spinal cord …
• ADA Issues New MASLD Guidelines Medscape A new consensus report from the American Diabetes Association (ADA) provides a practice-oriented framework for screening and managing metabolic dysfunction–associated steatotic liver disease (MASLD) in people with diabetes and prediabetes. Published online …
• European Shares Mostly Lower Amid Global Trade Tensions RTTNews European stocks were broadly lower on Monday as U.S. President Donald Trump's decision to double tariffs on steel and aluminum imports along with rising Sino-U.S. tensions threatened to rekindle global trade tensions. In economic releases, the downturn …
• 'Pharma Bro' Martin Shkreli Sees $10 Trillion Potential In Palantir, But Cautions: 'One Bad Quarter And It's Down 50%' Benzinga Former hedge fund manager Martin Shkreli expressed bullish views on Palantir Technologies Inc. PLTR while cautioning investors about the stock’s inherent volatility during an interview with popular PLTR investor Amit Kukreja. What Happened: Shkreli, …
• Banks, realty, FMCG: These 6 sectors may lead earnings growth in FY26; here’s why Business Today India Inc’s Q4 earnings are much better than estimated, according to Vinod Nair, Head of Research, Geojit Investments. In an interaction with Business Today, the market watcher said the broad market has done well with profit after tax (PAT) growth of 12% …
• Five things for pharma marketers to know: Monday, June 2, 2025   Medical Marketing and Media Why Summit Therapeutics’ surprise failed study is a win for Chinese biopharma deals. Summit and Akeso’s PD-1xVEGF bispecific hit on progression-free survival in a keenly-awaited Phase 3 lung cancer trial, but missed the other primary endpoint. (Barron’s)  …
• Nomura Boosts Nifty March 2026 Target To 26,140; Recommends Key Stock Picks News18 Last Updated:June 02, 2025, 13:49 IST Nomura observed that, despite overall earnings estimate reductions, India’s Q4 season saw more companies outperform than underperform Nomura observed that, despite overall earnings estimate reductions, India’s Q4 …
• Joe Lonsdale Slams Healthcare 'Cartels:' Urges AI, Regulatory Reform To Slash Costs, Reclaim Biotech From China Benzinga Palantir Technologies Inc. PLTR Co-Founder Joe Lonsdale delivered sharp criticism of America’s healthcare system during the Reagan National Economic Forum, calling for artificial intelligence adoption and regulatory reform to combat rising costs and China’ …
• Feature article - Nitrosamine mitigation: Delivering a dose of clarity in three key questions Speciality Chemicals Magazine Amit Chivate, senior market manager, Greater Asia & China, at Roquette Health & Pharma Solutions looks at practical strategies pharma producers can adopt to simplify their nitrosamine compliance processes and continue to assure patient safety More …
• Invidior: Drug maker ditches London for US City A.M. Monday 02 June 2025 8:23 am  |  Updated:  Monday 02 June 2025 8:24 am Share Facebook Share on Facebook X Share on Twitter LinkedIn Share on LinkedIn WhatsApp Share on WhatsApp Email Share on Email Some 88 firms left the London Stock Exchange last year, …
• French Firm Servier Drops Exclusive Deal For Selling High BP Drugs After Chemists' Pushback News18 Last Updated:June 02, 2025, 12:40 IST After successful mediation by offline chemists, Servier promptly withdrew the agreement – which is seen as a positive step towards preserving the fairness of open trade practices. All India Organisation of Chemists and …